Siglec-9 CRISPR/Cas9 KO Plasmid (h): sc-406675
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- Siglec-9 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the Siglec-9 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Siglec-9 CRISPR/Cas9 KO Plasmid (h) | sc-406675 | 20 µg | $397.00 |
Overview
SIGLEC9 encodes Siglec-9, a sialic acid–binding immunoglobulin-like lectin predominantly expressed on neutrophils, monocytes, and subsets of NK cells where it functions as an inhibitory receptor. Through immunoreceptor tyrosine-based inhibitory motif (ITIM)-dependent signaling and recruitment of phosphatases such as SHP-1/2, Siglec-9 dampens activation cues downstream of pattern-recognition and Fc receptor pathways, shaping cytokine release, degranulation, and oxidative burst. By sensing sialylated glycans on host or microbial surfaces, it contributes to immune homeostasis and modulation of inflammation at mucosal and vascular interfaces. Dysregulated SIGLEC9 signaling and altered sialylation landscapes have been studied in settings including chronic inflammatory disease, infection biology, and tumor-associated immune suppression within the myeloid compartment.
Siglec-9 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the SIGLEC9 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the SIGLEC9 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the SIGLEC9 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish Siglec-9 protein expression.
This CRISPR knockout system enables efficient generation of SIGLEC9-deficient cell models for investigation of Siglec-9 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting SIGLEC9 exon(s) critical for Siglec-9 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple SIGLEC9 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by Siglec-9 CRISPR/Cas9 KO Plasmid (h) and Siglec-9 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the SIGLEC9 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by Siglec-9 HDR Plasmid (h) and Siglec-9 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by SIGLEC9 homology arms to support homology-directed repair at defined SIGLEC9 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.